The present disclosure provides -diketones or analogs thereof, that activate Wnt/-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

A process prepares a compound containing at least one cyclic monothiocarbonate group, wherein a salt of an acidic compound with at least one acidic hydrogen atom is reacted with a compound of formula (I), ##STR00001##
wherein one of the groups R.sup.1 to R.sup.4 is a group of formula (II), -A-X, with A representing an organic group with at least one carbon atom and X representing a halide, and the remaining groups R.sup.1 to R.sup.4 independently from each other represent hydrogen or an organic group with 1 to 50 carbon atoms.

Disclosed generally relates to C5a receptor inhibitors, compositions thereof, methods of use thereof, and methods of preparation thereof.

Disclosed generally relates to C5a receptor inhibitors, compositions thereof, methods of use thereof, and methods of preparation thereof.

The present disclosure provides -diketones or analogs thereof, that activate Wnt/-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

The present disclosure provides -diketones or analogs thereof, that activate Wnt/-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

There are disclosed certain 2,4,6-trisubstituted 1,3,5-triazine compounds of Formula (I),

##STR00001##

and pharmaceutically acceptable salts thereof, together with compositions containing them and their use in therapy. The compounds are modulators of CX.sub.3CR1 and are thereby particularly useful in the treatment or prophylaxis of cardiovascular disorders such as non-ischemic dilated cardiomyopathy and heart failure.

The present disclosure provides ?-diketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

The present disclosure provides ?-diketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

The present invention relates to N-acylimino compound of formula (I):

##STR00001## wherein X is O or S, in particular O; m is an integer selected from 0, 1, 2, 3, 4, 5 or 6; Het is a 5 or 6 membered carbon-bound or nitrogen-bound heterocyclic ring, W.sup.1W.sup.2W.sup.3W.sup.4 represents a carbon chain group connected to N and CN, and thus forming a saturated, unsaturated, or partially unsaturated 5 or 6 membered nitrogen containing heterocycle, wherein W.sup.1, W.sup.2, W.sup.3 and W.sup.4 each individually represent CR.sup.vR.sup.w, R.sup.1, R.sup.2 may be hydrogen, halogen, etc. R.sup.3 may be hydrogen, halogen, CN, C.sub.1-C.sub.6-alkyl, etc. R.sup.4a, R.sup.4b if present, may be hydrogen, halogen, C.sub.1-C.sub.6-alkyl, etc. or R.sup.3 and R.sup.4a may also form a double bound, R.sup.5 may be hydrogen, halogen, CN, C.sub.1-C.sub.6-alkyl, C.sub.1-C.sub.6-alkoxy, C.sub.1-C.sub.6-alkylthio, C.sub.1-C.sub.6-alkylsulfinyl, C.sub.1-C.sub.6-alkylsulfonyl, C.sub.2-C.sub.6-alkenyl, C.sub.2-C.sub.6-alkynyl, C.sub.2-C.sub.6-alkenylthio, C.sub.2-C.sub.6-alkenylsulfinyl, C.sub.2-C.sub.6-alkenylsulfonyl, C.sub.2-C.sub.6-alkynyl, C.sub.2-C.sub.6-alkynylthio, C.sub.2-C.sub.6-alkynylsulfinyl, C.sub.2-C.sub.6-alkynylsulfonyl, etc. R.sup.3 and R.sup.5 together may also form with the carbon atom they are bound to, a 3-, 4-, 5- or 6-membered saturated partially unsaturated carbocycle or heterocycle.

The invention also relates to the use of the N-acylimino heterocyclic compounds, their stereoisomers, their tautomers and their salts, for combating invertebrate pests. Furthermore the invention relates also to methods of combating invertebrate pests, which comprises applying such compounds.